Impact of medication adherence on the effectiveness of @entity27101 for the treatment of transfusional @entity68 overload in XXXX .

@entity1 @entity8 @entity68 @entity2590 @entity2251 @entity27101 @entity204 @entity4667
WHAT IS KNOWN AND OBJECTIVE: Regular blood transfusions in the management of @entity2590 ( @entity2590 ) often lead to @entity68 overload. The main objective of this study was to evaluate the impact of medication adherence on the effectiveness of @entity27101 for the treatment of transfusional @entity68 overload in @entity1 with @entity2590 . Secondary objectives were to describe treatment effectiveness and safety in daily clinical practice. METHODS: A longitudinal, retrospective, observational study was carried out in a university hospital. The inclusion criteria were age over 18 years, @entity2590 diagnosis and treatment with @entity27101 for transfusion-dependent @entity68 overload during the period of study (from January 2011 to April 2015). Treatment effectiveness was estimated by serum ferritin (SF), and adherence was measured by medication possession ratio (MPR). Clinically relevant analytical alterations during the treatment and reasons for treatment discontinuation were also assessed. RESULTS: Thirty-five @entity1 were included in the study. Median SF at baseline was 1636  g/L, and it decreased to 1399  g/L during follow-up. The median adherence rate was 92%, although only 54  8% of the @entity1 maintained @entity27101 adherence >= 90% during the whole duration of treatment. Adherence rate was inversely correlated to SF (r = -0  288, P = 0  004). The median ( @entity4667 , @entity2251 ) duration of treatment was 11 (3  0, 37  8) months. The most common reasons for treatment discontinuation were @entity8 (35%) and @entity1 's @entity204 (25%). WHAT IS NEW AND CONCLUSION: @entity27101 's effectiveness, measured by the decrease in SF, was significantly better in adherent @entity1 . The most frequent reason for treatment discontinuation was @entity8 . Developing strategies to improve @entity27101 treatment adherence and monitoring renal function in those @entity1 should be key points in pharmaceutical care.
